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Because of the time factor involved, it would be 
an impossible task to present the vast body of 
biochemical information accumulated during the 
last decade on the endocrine aspects of pregnancy. 
However, certain key points can be made concerning 
the feto-placental unit and the hormone levels and 
effects in normal gestation. These concepts will be 
discussed not merely for their academic value, but 
also as a base to evaluate our present diagnostic 
and therapeutic endeavors in obstetrical practice. 
With the audience's indulgence, an occasional per-
sonal conjecture will be interjected concerning 
hormonal mechanisms and clinical practices. 
Feto-Placental Unit. The fetus and the placenta 
are incomplete steroidogenic systems. They lack the 
capability of synthesizing all necessary steroidal 
hormones from more simple precursors in contrast 
to the ovaries, testes, and adult adrenal cortex. To 
complete the task a well-coordinated interdigitation 
of the synthetic capabilities of fetus, placenta, and 
mother is required. Since the mother is involved, 
one wonders whether the term "feto-materno-
placental unit" would not be more appropriate. 
First the fetal adrenal cortex and then the 
placenta will be discussed; hopefully, emphasizing 
the information which may have practical clinical 
significance. 
A. Adrenal Cortex. The fetal zone of the 
adrenal cortex persists only during gestation, con-
stitutes about 80% of the gland, and is active in 
steroid metabolism. In the first trimester, it is 
believed this zone is primarily stimulated by human 
chorionic gonadotrophin (HCG); ACTH gaining 
prominence in control thereafter. 
The biochemical capabilities and limitations of 
the fetal adrenal cortex are shown in Fig. 1. Utilizing 
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acetate as a precursor, the fetal zone more readily 
synthesizes the t::..5-3{3 hydroxysteroids pregneno-
lone and dehydroepiandrosterone (DHEA) than 
the t::..4-3 ketosteroids such as cortisol and aldo-
sterone. This is because of a relative block in 3{3-
hydroxy dehydrogenase and t::..5 isomerase activity. 
Thus, the synthesis of large amounts of DHEA and 
its sulfate is favored, and they are transported to the 
placenta as such or after 16a-hydroxylation by the 
fetal adrenal or liver. The placenta can metabolize 
these androgens to estrogens as will be shown 
shortly. 
However, such a biosynthetic lack would 
leave the fetus in jeopardy because of a cortisol and 
aldosterone deficiency. This is rectified by the 
fact that the fetal zone can utilize the readily 
available placental progesterone to produce these 
needed hormones. In fact, after the tenth week of 
gestation, the increasing placental progesterone 
secretion may enhance the 17,a, 21, and 11{3 
hydroxylase capability of the fetal adrenal cortex 
to produce the corticoids . Also, the ready passage of 
maternal cortisol across the placenta is a secondary 
protective mechanism. 
B. Placenta. This endocrine organ is incapable 
of synthesizing large quantities of progesterone and 
estrogens from the simple precursor acetate. How-
ever, it can efficiently convert maternal plasma 
cholesterol to progesterone as shown in Fig. 2. This 
is clinically important for it means that an intact ma-
ternal-placental circulation will produce essentially 
normal progesterone levels even though a fetal de-
mise has occurred. The progesterone produced by the 
placenta can be metabolized by the mother and fetus 
to less active progestational metabolites or can be 
utilized by the fetal adrenal as already described. 
Since a 17 a-hydroxy lase deficiency in the placenta 
precludes the conversion of progesterone to andro-
gens and subsequently estrogens, another mechanism 
must exist for placental estrogen synthesis. 
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Fig. I-Pathways of steroid metabolism in the human fetal adrenal cortex. The major secretory products are boxed in. (Reprinted 
with permission from Villee. New Eng. J. Med. 281: 473, 1969.) 
As depicted in Fig. 3, the placenta produces 
estrogens from androgens of maternal and fetal 
adrenal origin. Androstenedione, DHEA, and testos-
terone are converted by the placenta to estradiol 
and estrone. It is estimated that the mother and 
fetus each contribute about 50% of the androgens 
which are made into these 2 estrogens. Since the 
ability to 16.a-hydroxylate androgens is essentially 
limited to the fetal adrenal and liver, the fetus is 
the major contributor of 16a-hydroxylated andro-
stenedione, DHEA, and testosterone which are 
converted by the placenta to estriol. The maternal 
contribution to estriol at term is less than 10% and 
probably arises from her adrenal androgens which 
escape conversion to estradiol and estrone on passage 
through the placenta to fetus. In the fetus, however, 
her androgens can be hydroxylated at the 16a 
position before recirculation back to the placenta 
where synthesis to estriol can occur. 
The above information indicates that the 
clinical assay in pregnancy of plasma progesterone 
or its major metabolite, pregnanediol, in the urine 
would mirror placental integrity. On the other hand, 
estrogen assays, particularly urinary estriol, would 
reflect fetal integrity. 
Hormone Secretion Patterns and Effects in Nor-
mal Gestation. 
A. Progesterone. The corpus luteum appears 
to be the initial source of progesterone in preg-
nancy. Subsequently, it is produced by the placenta 
in increasing amounts from maternal cholesterol. 
This transition of secretion from one gland to the 
other is shown in Fig. 4. Both plasma 17a-hydroxy 
progesterone and progesterone of corpus luteum 
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Fig. 2-Principal precursors and metabolites of progesterone 
in the human placenta. The major steroid secreted by the 
placenta (progesterone) is boxed in. (Reprinted with per-
mission from Villee. New Eng. J. Med. 281 :473, 1969.) 
origin are seen to peak at 3-4 weeks after ovu-
lation. At 6-8 weeks post-ovulation, the proges-
terone reaches a nadir while the 1 7 a-hydroxy pro-
gesterone continues to decline. Since the placenta 
lacks significant 17a:-hydroxylase capability, it is as-
sumed that the secondary rise in progesterone reflects 
placental function. It is of interest to note that 
HCG-believed to maintain the corpus luteum of 
pregnancy-continues to rise while both hormones 
of corpus luteum origin are declining. 
The secondary rise in placental progesterone 
continues to increase progressively to a maximum 
plateau at 36-40 weeks. This is seen from our data 
in Fig. 5, where the level at 8 weeks of 2 micro-
grams % increases linearly to about 14 micrograms 
% at term. The curve seems to parallel that of 
placental weight and is of similar configuration to 
that of urinary pregnanediol as depicted in Fig. 6. 
It is important to note that no significant drop 
in progesterone occurs prior to labor. However, 
during parturition we and others have found a 
slight downward trend of mean values and this may 
be a reflection of placental ischemia secondary 
to the uterine contractions. There is a rapid drop 
in the plasma progesterone after delivery of the 
placenta verifying the hormone's short half-life. 
It has been estimated that the term placenta 
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produces 200-300 mgms of progesterone daily. The 
role of this large amount of hormone is not well 
defined, but possible metabolic functions are: 
1. The maintenance of growth and development 
of the fetus; for example, it is a precursor 
steroid for the synthesis of corticoids by the 
fetal adrenal cortex. 
2. An immunosuppressive agent to protect the 
feta-placental homotransplant. 
3. A defense mechanism acting on the myo-
metrium to prevent premature expulsion of 
the fetus. 
4. Prepare the breasts for lactation. 
5. Mediate a variety of biochemical events; 
for example, antagonize at the renal tubule 
the effects of the increased aldosterone con-
centration found in pregnancy. 
B. The Estrogens. Quantitatively, estriol is the 
major estrogen of human pregnancy. Its biologic 
potency, however, is significantly less than that of 
estradiol and estrone. The urinary excretion curve 
for estriol is presented in Fig. 7; the amount rising 
from low early levels to high levels at term. An 
acceleration in the increase is apparent during the 
last few weeks. There seems to be a good correla-
tion between the estriol curve and that for the 
fetal weight. Klapper, reviewing the literature, found 
the average levels to be 10.1, 14.2, 19.8, and 26 
mgms at 28, 32, 36, and 40 weeks respectively. 
Similar curves for urinary estradiol and estrone 
have been found, but the amounts are in the micro-
gram range. These two estrogens, like estriol , prob-
ably reflect the status of the feta-placental unit. 
Munson in our group has assayed unconjugated 
estradiol in the plasma of normal · pregnancies. A 
mean value of 200 nanograms % in early pregnancy 
(9-16 weeks) rose to 1196 nanograms % dur-
ing the last 8 weeks. A curve configuration similar to 
urinary estrogen excretion patterns was obtained. 
I suspect that the estrogenic effects of preg-
nancy are primarily due to estradiol, the most po-
tent of these 3 estrogens. It mediates the growth and 
function of the maternal reproductive organs and 
probably is important to fetal growth and develop-
ment. The reason for the large mass of estriol pro-
duction is not clear. There is little evidence at the 
moment that it is involved in the start of human 
labor. 
A biochemical effect of estrogen in pregnancy 
or when given to a woman exogenously is the in-
creased liver synthesis of certain steroid hormone 
binding globulins. The increased hormone binding 
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Fig. 3- Synthesis of estrogens by the human placenta. The pathways for the conversion of C19 steroids to estrogens are shown. 
The major estrogens secreted by the placenta are boxed in. (Reprinted with permission from Villee. New Eng. J. Med. 281: 473, 1969.) 
results in elevated concentrations of serum thy-
roxine (also the PBI), plasma cortisol, and testos-
terone. However, the amount of free or unbound 
hormone, and presumably the biologically active 
fraction, is unchanged. Unless this estrogen effect 
is taken into account, the clinician can be misled 
by the elevated laboratory result. The only excep-
tion to this physiologic change is for plasma cortisol 
in pregnancy. The large amount of placental pro-
gesterone in pregnancy plasma competes with corti-
sol for binding sites on transcortin and increases 
the free cortisol fraction. Therefore the pregnant 
woman is actually in a state of mild adrenal hyper-
corticism. 
C. Human Placental Lactogen (HPL). This 
polypeptide hormone secreted by the syncitial 
trophoblast is immunologically similar to but distinct 
from human growth hormone. Metabolically it ap-
pears to be a weaker growth hormone. Its pattern 
of secretion into the blood is shown in Fig. 8; the 
increasing concentration throughout pregnancy 
parallels the curve for placental weight. Like pro-
gesterone, its blood concentration reflects placental 
rather than fetal integrity. Fetal death may not 
significantly drop the level for a period of time as 
long as the materno-placental circulation is intact. 
The placental secretion is essentially unidirectional 
into the mother; much lower levels being found in 
YAN NONE: HORMONAL CHANGES IN PREGNANCY .47 
HCG 
i 
HMG 100 
JU 
,,,,,.... __ _.. 
~· .,,,. 
~, 
, 
f 10 -0 I 
' 
J> 
I (,/') 31: -0 
? ,?-Oj~ J> r-10 :c 2.0~ b I t ("") 31: 
~ ~ .. \ 1.0 c;-, J> E 
.I' c: 0 _, 
0 I \ /, ........ 0 I \ / 3 :c ........ 
-at I ;,P/ -0 ~ .,. ::l. I ::u 
w I ' . _,,,./ 0.1 ~ 0 
°'°"' 
:z 0 c;-, 0 
' 
f'T'1 
a: 5 1.0 (,/') w I ...... ~ I f'T'1 (/') ::u 
LL.I I 0 C> 
0 I 0.01 z a: I 
,.,, 
a.. , 
--== 
<( 
' 
'° ........ 
::E I 5 (/') 
<( I 0 
_J 3 
a.. 0 0 0 -
0 4 8 12 16 
WEEKS I 
Fig. 4- Mean plasma levels of progesterone, 17-hydroxyprogesterone, and HCG following induction of ovulation with HMG-HCG 
and subsequent conception. (Reprinted with permission from Yoshimi, et al. J. Clin. Endocr. 29: 225, 1969.) 
the fetus. The daily production can be as high as 
400 mgms. 
Possible roles of HPL are preparation of the 
breasts for successful lactation and indirect growth 
hormone effects. These include increased nitrogen 
retention, increased maternal fatty acid utilization 
sparing glucose for transmission to the fetus. The 
fetus, like the adult brain, utilizes essentially glucose 
only for its energy requirements. HPL is antagonistic 
to insulin and as a consequence may be an important 
factor in the diabetogenic effect of pregnancy. 
D. Human Chorionic Gonadotrophin (HCG). 
The blood and urine levels of this glycoprotein 
secreted by the cytotrophoblast differ from the 
curves seen for the previousiy discussed horomones 
;md is shown in Fig. 9. The concentration in the 
blood peaks at about 60 days, then decreases to 
% to V:3 of the peak value throughout pregnancy 
with a lower secondary rise at term. 
Its role in pregnancy is not clear, but tradition-
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Fig. 5-The plasma progesterone concentration in normal pregnancy expressed as micrograms 3. One hundred and t1:Velve of these 
179 determinations were reported previously. Note the progressive increase in concentration with advancing gestation. (Reprinted 
with permission from Yannone. Steroids 13: 773, 1969.) 
ally is believed to maintain the corpus luteum of 
pregnancy. It may also regulate steroid secretion 
by other glands; its possible ACTH effect on the 
fetal adrenal cortex in early pregnancy has already 
been mentioned. 
Clinical Implications. 
A. Progesterone and Pregnancy Status. Plasma 
progesterone and urinary pregnanediol have been 
measured in a variety of obstetric disorders to prog-
nosticate dysfunction or to establish its presence. 
Such diagnostic attempts have been less than satis-
factory. Probably the primary reason for this is that 
the hormone concentration can remain in the nor-
mal range even with fetal death as long as the utero-
placental circulation is intact. Other problems are 
the wide day to day variation in the same individual 
and the overlap of values in normal and abnormal 
gestation. Even when the hormone concentration is 
definitely subnormal, it is usually the effect of an 
uncorrectable dysfunction rather than the cause. 
Therefore exogenous progesterone substitution is 
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YANNONE: HORMONAL CHANGES IN PREGNANCY 
• 
49 
Mg Estriol/24 hrs 
; • ""'50 
I 
I • 
I • 
I : .. 
•• I • 
r. . 
I • • I •• • 40 
I • : .. 
' ... I 
I 
I· 
• 
• 
I • I 
• 
• 
I 
I • • • ~ 3o 
. l . . . 
l i: \ 
,: • • -,= • • :: 
.,, . . ..... 
, . . . . 
,t. • • .·.: •• :. 
,, . .. . .... 
~ ••• \ ••••• - 20 
,, . . .:.•\ .... 
,, • • • . :i. • •\ 
,, . . ...... . 
. . , . . . . . . .. 
,, . . . . . . . . . 
• ,*' • • • • • • .. .. •••• 
,,, . . : .. : . .. .. .. . 
-~ . .. . . .. .. .. ... 
-:' • • I • ••• • •• • • • • • • 
-- . - . .. . .... . . 
. ..- . . . . . . ·ii· ... . . \ . , .. .. .. . . , .   ,..  . _ .. 
.. • __ .. ~- .: • • • • • • • , ........ :- '"' ~ 10 
.. ~ ,, . .. .. . . . . . . .. -
--. .. , ..... ,.. . . . .. . . ·:-- . 
-- . . . . . .._.. . ....... -
. . --: . ., ........................ --· 
,., _. • ••:-. I• • r._ • .,.. •• • • .... .. 
.... -:-~·· ... ,: ... ~.· ...... .,.. ... -\•• .. · ......... .. 
---··'· .. ., . ,... . .. . . . -·- -- .. ,.-- ... .!~ • • • •• • •• • 1 ' ---
...... .;::.~::~:. •• • :·~ • I• ' .,. ...... --·- . 
... ,,:..1e: . :,. -c.•.-i: •• :: •• :a--"····· 
L'\:i..;.,!t.'- . ----~---~-
I I I I I I • 10 15 20 25 30 35 40 
Weeks of pregnancy 
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New York: Harper and Row, 1971.) 
generally of little value. Similar problems are en-
countered when serial assays for HPL are used 
as a diagnostic tool. 
B. Progesterone and Adequacy of the Corpus 
Luteum; Abortion. Of probable clinical value are the 
use of serial plasma progesterone or urinary preg-
nanediol assays to evaluate corpus luteum ade-
quacy in certain types of infertility and possibly a 
few cases of first trimester abortion. Although the 
majority of such abortions are due to uncorrectable 
causes such as chromqsomal defects, a few could 
be due to corpus luteum dysfunction with dishar-
monious transition of steroid hormone production to 
the placenta. When such corpus luteum inadequacy 
is incriminated, correction of the infertility or pre-
vention of another abortion may be achieved by 
insuring an adequate corpus luteum. However, not 
by the use of exogenous progesterone replacement, 
but rather by the judicious use of ovulatory in-
ductors such as Clomid® or the gonadotrophins to 
insure normal follicular maturation which will result 
in a normal corpus luteum. 
C. Progesterone-Term and Premature Labor. 
Elucidation of the mechanism which institutes labor 
wou~d enhance our capability to induce labor for 
medical or convenience reasons and to stop pre-
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mature labor. The theory most often advanced to 
explain the mechanism which institutes parturition 
is the progesterone-block concept. This maintains 
that progesterone suppresses myometrial contractility 
during gestation and labor begins upon withdrawal 
of the hormone. However, our studies and those of 
others have not shown a significant and consistent 
drop in circulating progesterone prior to labor's 
onset. These findings do not exclude a protective 
role for progesterone as an effective decrease may 
occur that is not apparent in the circulating levels. 
One possibility that we investigated was that the 
concentration of free and active progesterone de-
creased with advancing pregnancy because of in-
creased protein binding of the hormone. However, 
we found the percentage of binding to remain 
constant throughout pregnancy, which meant that 
as the total progesterone concentration rose so did 
the concentration in the bound and unbound frac-
tions. With this negative finding we have turned to 
studies which may show decreased progesterone 
levels within the myometrial cells. Our results are 
too preliminary to draw conclusions. · 
In spite of our ignorance as to how labor starts, 
we are not totally devoid of therapeutic agents. Within 
reason labor can be induced at term with oxytocin. 
It is much less effective earlier in pregnancy. Pros-
taglandins such as F2a appear to be effective at term 
as well as earlier in gestation. However, on parenteral 
use in the first 2 trimesters, the therapeutic-toxic 
difference becomes too narrow. This problem may 
be overcome by using the prostaglandin locally in 
the vagina to induce an indicated abortion or 
premature labor. Lastly, with judicious use of 
intravenous alcohol in premature labor, the expul-
sion of the fetus can be delayed a few days to a 
few months in about 65 % of the patients. 
D. Estriol and Complicated Pregnancies. The 
most important clinical consideration at the moment 
is the value of serial estriol determinations in the 
management of high-risk pregnancies. While it can 
be helpful in certain complications of pregnancy such 
as diabetes mellitus, toxemia, and dysmaturity to 
evaluate the fetal status, it is not without pitfalls. 
First the clinician is at the mercy of the quality 
control of the laboratory doing his assays. Inaccurate 
results can lead to false security or ill-timed termi-
nation of pregnancy. Even with a good laboratory, 
the results may not always reflect the true status of 
the pregnancy. Unfortunately, our knowledge of 
estrogen metabolism in pregnancy is inadequate to 
explain such discrepancies any better than it can 
explain why Rh isO:.immunized jeopardized preg-
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nancies do not show subnormal estriol levels. Even 
more disconcerting is the fact that excellent clinicians 
using good laboratories are reporting perinatal 
losses in diabetic pregnancies no better or even 
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nancy, First Edition. New York: Harper and Row, 1971.) 
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worse than reputable clinics have reported prior to 
the availability of this assay. So far there has not 
been any conclusive evidence that a marked 
reduction in fetal mortality has been obtained be-
cause of estriol determination. In this light, the 
overzealous utilization of estriol assays as a sub-
stitute for rather than an adjunct to clinical manage-
ment is foolhardy. 
As an adjunct to clinical judgment, the literature 
seems to agree on certain helpful points. These 
are as follows: 
1. Significant day to day variation requires 
serial assays to determine a mean for each 
patient. 
2. In a suspect pregnancy, weekly or biweekly 
assays should be done from about the 30th 
week up to the time of reasonable maturity 
(about 34th week) at which time daily or 
every other day determinations should be 
carried out. 
3. In any complicated pregnancy which is 34 
weeks or beyond, any precipitous fall from 
normal levels of urinary estriol and which 
is verified over 2 or more consecutive days 
dictates immediate delivery. 
4. Chronic low estriol levels in preeclamptic 
toxemia or dysmaturity do not necessitate 
interruption unless there is a precipitous 
drop from the low mean. Such babies left 
in utero may not grow very much, but they 
do achieve greater maturity. 
5. Urinary estriol levels can be expected to 
be low in mothers with anencephalic mon-
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sters or on glucocorticoid therapy for medi-
cal reasons. 
The development of new specific and sensitive 
hormone assay methods and the increase in sophisti-
cation of metabolic studies has given us an impres-
sive array of biochemical information concerning 
the physiology and endocrinology of pregnancy. 
However, the application of this knowledge to 
the improvement of obstetrical care has been 
difficult. This should not discourage us as medical 
science must like the infant learn to crawl before 
it can walk. Eventually we shall have all the facts 
needed to obtain the obstetrical results that we 
all desire. We have had a promising start. 
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